{"DataElement":{"publicId":"2950606","version":"1","preferredName":"Agent Randomization Assignment Name","preferredDefinition":"The name that describes the administration of agent at the time of randzomization.","longName":"AGT_RAND_ASSIGN_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2495389","version":"1","preferredName":"Agent During Randomization Administered","preferredDefinition":"information related to the administration of agent at the time of randzomization (an experiment or clinical trial in which subjects are assigned by chance to separate groups that compare different treatments).","longName":"AGT_DUR_RAND_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2495387","version":"1","preferredName":"During Randomization Administered","preferredDefinition":"At some point in a given period of time.:The allocation of individuals to groups, e.g., for experimental and control regimens, by chance. (On-line Medical Dictionary):Given.","longName":"C25490:C25196:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"During","conceptCode":"C25490","definition":"At some point in a given period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"188BCCA7-A4DE-41D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-14","modifiedBy":"ONEDATA","dateModified":"2006-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"188BCCA7-A4EF-41D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2950602","version":"1","preferredName":"Agent Assignment Name","preferredDefinition":"The name of the appointed agent.","longName":"AGT_ASSIGN_NM","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Celecoxib","valueDescription":"Celecoxib","ValueMeaning":{"publicId":"2577801","version":"1","preferredName":"Celecoxib","longName":"2577801","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7531E665-39A7-B791-E040-BB89AD432F47","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","deletedIndicator":"No"},{"value":"Zileuton and Celecoxib","valueDescription":"Zileuton And Celecoxib","ValueMeaning":{"publicId":"2950604","version":"1","preferredName":"Zileuton And Celecoxib","longName":"2950604","preferredDefinition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zileuton","conceptCode":"C26667","definition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-39B7-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7531E665-39D0-B791-E040-BB89AD432F47","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","deletedIndicator":"No"},{"value":"Zileuton","valueDescription":"Zileuton","ValueMeaning":{"publicId":"2950661","version":"1","preferredName":"Zileuton","longName":"2950661","preferredDefinition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zileuton","conceptCode":"C26667","definition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75442F1B-EFC8-748B-E040-BB89AD431683","latestVersionIndicator":"Yes","beginDate":"2009-10-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75442F1B-EFE1-748B-E040-BB89AD431683","beginDate":"2009-10-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-06","modifiedBy":"ONEDATA","dateModified":"2009-10-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2950601","version":"1","preferredName":"Agent Assignment Name","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Assignment; an undertaking that you have been assigned to do.:The words or language units by which a thing is known.","longName":"C1708:C25426:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-3982-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-3993-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"MAESKEB","dateModified":"2009-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"2936518","version":"1","longName":"Polyphenon E in Women w/ Modulation of Arachidonic Acid","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Randomization Assignment","type":"Preferred Question Text","description":"Randomization Assignment","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-39E2-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"MAESKEB","dateModified":"2009-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}